title: Mutation screening of the CDKN2A promoter in melanoma families.
abstract: Germline mutations of CDKN2A, at 9p21, are responsible for predisposition to melanoma in some families. However, evidence of linkage to 9p21 has been demonstrated in a significant proportion of kindreds with no detectable mutations in CDKN2A. It is possible that mutations in noncoding regions may be responsible for predisposition to melanoma in these families. We have analyzed approximately 1 kb of the CDKN2A promoter upstream of the start codon in an attempt to identify causal mutations in 107 melanoma families. Four sequence variants were detected. Two of these (A-191G and A-493T) did not segregate with disease and were present in a control population at a comparable frequency, indicating that they are unlikely to predispose to melanoma. The A-493T variant appeared to be in linkage disequilibrium with the previously described CDKN2A polymorphism Ala148Thr. The variant G-735A was detected in the control population, but segregation of this variant with melanoma within families could not be discounted. The fourth variant (G-34T), located in the 5' UTR, creates an aberrant initiation codon. This variant appeared to segregate with melanoma and was not detected in a control population. G-34T has recently been identified in a subset of Canadian melanoma families and was concluded to be associated with predisposition to melanoma. The creation of an aberrant initiation site in the 5' UTR may have an important role in carcinogenesis in a small percentage of families; however, mutations in the CDKN2A promoter appear to have a limited role in predisposition to melanoma.
authors.affiliation: ICRF Genetic Epidemiology Laboratory, St. James' University Hospital, Leeds, England.
authors.forename: M
authors.initials: M
authors.lastname: Harland
authors.forename: E A
authors.initials: EA
authors.lastname: Holland
authors.forename: P
authors.initials: P
authors.lastname: Ghiorzo
authors.forename: M
authors.initials: M
authors.lastname: Mantelli
authors.forename: G
authors.initials: G
authors.lastname: Bianchi-Scarrà
authors.forename: A M
authors.initials: AM
authors.lastname: Goldstein
authors.forename: M A
authors.initials: MA
authors.lastname: Tucker
authors.forename: B A
authors.initials: BA
authors.lastname: Ponder
authors.forename: G J
authors.initials: GJ
authors.lastname: Mann
authors.forename: D T
authors.initials: DT
authors.lastname: Bishop
authors.forename: J
authors.initials: J
authors.lastname: Newton Bishop
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods*; D018095:Germ-Line Mutation / Q000235:genetics; D006147:Guanine / Q000032:analysis; D006801:Humans; D015810:Linkage Disequilibrium / Q000235:genetics; D008545:Melanoma / Q000235:genetics*; D010375:Pedigree; D017354:Point Mutation; D011401:Promoter Regions, Genetic / Q000235:genetics*; D013941:Thymine / Q000032:analysis
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D004273:DNA, Neoplasm; D006147:Guanine; D013941:Thymine